All News

A recent study shows decreased use of multiple types of contraception among patients struggling with OUD.

The approval was based on a confirmatory trial that found the therapy slowed disease progression compared with placebo.

Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.

The increase is expected to be somewhat offset by the impact of biosimilars coming to market and more care being provided in outpatient settings.

What's on the agenda for FTP in the upcoming month?

Odevixibat can now be used to treat cholestatic pruritus in young patients with Alagille syndrome (ALGS).

Delayed prophylaxis start and intermediate dose intensity of factor VIII prevents bleeds, but at a cost of more joint damage and possibly a lower QOL.

Your weekly roundup of the latest news from Drug Topics®.

What stood out on Sunday and Monday at the 2023 ASHP Summer Meetings in Baltimore?

Your weekly roundup of the latest news from Drug Topics®.

Advisers with the FDA endorse a monoclonal antibody treatment for RSV in children, AstraZeneca and Quell sign a $2 billion agreement, and HSS hopes to strengthen the pediatric workforce.

The newly approved at-home test was effective in trials, correctly identifying 98.7% of negative and 92.9% of positive samples for individuals with symptoms of upper respiratory infection.

Which masks (if any) serve as the best protection against wildfire smoke, and what do experts say about home appliances like air conditioners?

A survey shows cancer centers are struggling, Google expands its generative AI into health care, and the WHO announces enhanced collaboration with the Global Fund.

The median annual cost for new oncology medicines launched in 2022 was $260,000, up from $63,534 10 years ago, an IQVIA report finds.

Cue Health gets FDA’s first de novo approval for at-home COVID-19 test, Novavax says its new vaccine will fight new variants and HHS creates new cert standards for peer support workers.

Existing evidence-evaluation frameworks are not sufficiently targeted toward the specific factors relevant to digital health products, they argue.

Merck sues the federal government, the FDA will allow cancer drug imports from China, and a drug from GSK shows promise for endometrial cancer treatment.

The combination of Lynparza and abiraterone reduced the risk of disease progression or death by 76% vs. abiraterone alone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.

Patients were more likely to require ICU admission.

Mandy Cohen is set to become the next CDC director, Medicare will cover a new class of Alzheimer’s drugs, and the WHO announces a landmark digital health initiative.

Your weekly roundup of the latest news from Drug Topics®.

More than 11.6 million treatment courses of the medication have been prescribed in the U.S. to date.

Individuals with type 1 diabetes (T1D) had brain atrophy patterns equivalent to a brain age about 6 years older than their actual age.